Literature DB >> 25092581

Managing overweight and obesity in adults to reduce cardiovascular disease risk.

Jon O Ebbert1, Muhamad Y Elrashidi, Michael D Jensen.   

Abstract

Obesity is a leading preventable cause of death and disability worldwide. Obesity increases the risk for clinically identifiable risk factors for cardiovascular disease (CVD) as well as a host of other metabolic, sleep, and orthopedic disorders. Coordinated and systematic interventions are needed to manage obesity and reduce these risks. The Obesity 2 Expert Panel updated the previous guidelines and produced the "Guideline for the Management of Overweight and Obesity in Adults." The Panel used data from publications from years 1999 to 2011 to address five critical questions, provide evidence statements, and recommend creation of a treatment algorithm to guide decision making about clinical care. The current review discusses the evidence statements pertaining to CVD risk in the assessment and management of patients who are overweight and obese. We summarize the FDA-approved medications for the treatment of overweight and obesity and their impact on CVD risk and risk factors, as well as ongoing clinical trials which will further inform clinical practice.

Entities:  

Mesh:

Year:  2014        PMID: 25092581      PMCID: PMC4148643          DOI: 10.1007/s11883-014-0445-x

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  22 in total

1.  Multicenter, placebo-controlled trial of lorcaserin for weight management.

Authors:  Steven R Smith; Neil J Weissman; Christen M Anderson; Matilde Sanchez; Emil Chuang; Scott Stubbe; Harold Bays; William R Shanahan
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

2.  Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial.

Authors:  Rena R Wing
Journal:  Arch Intern Med       Date:  2010-09-27

3.  Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study.

Authors:  Patrick M O'Neil; Steven R Smith; Neil J Weissman; Meredith C Fidler; Matilde Sanchez; Jinkun Zhang; Brian Raether; Christen M Anderson; William R Shanahan
Journal:  Obesity (Silver Spring)       Date:  2012-03-16       Impact factor: 5.002

4.  Bariatric surgery versus intensive medical therapy in obese patients with diabetes.

Authors:  Philip R Schauer; Sangeeta R Kashyap; Kathy Wolski; Stacy A Brethauer; John P Kirwan; Claire E Pothier; Susan Thomas; Beth Abood; Steven E Nissen; Deepak L Bhatt
Journal:  N Engl J Med       Date:  2012-03-26       Impact factor: 91.245

Review 5.  New obesity agents: lorcaserin and phentermine/topiramate.

Authors:  Joshua W Fleming; Katie S McClendon; Daniel M Riche
Journal:  Ann Pharmacother       Date:  2013-06-25       Impact factor: 3.154

6.  Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.

Authors:  Kishore M Gadde; David B Allison; Donna H Ryan; Craig A Peterson; Barbara Troupin; Michael L Schwiers; Wesley W Day
Journal:  Lancet       Date:  2011-04-08       Impact factor: 79.321

7.  A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.

Authors:  Meredith C Fidler; Matilde Sanchez; Brian Raether; Neil J Weissman; Steven R Smith; William R Shanahan; Christen M Anderson
Journal:  J Clin Endocrinol Metab       Date:  2011-07-27       Impact factor: 5.958

8.  Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial.

Authors:  Sayeed Ikramuddin; Judith Korner; Wei-Jei Lee; John E Connett; William B Inabnet; Charles J Billington; Avis J Thomas; Daniel B Leslie; Keong Chong; Robert W Jeffery; Leaque Ahmed; Adrian Vella; Lee-Ming Chuang; Marc Bessler; Michael G Sarr; James M Swain; Patricia Laqua; Michael D Jensen; John P Bantle
Journal:  JAMA       Date:  2013-06-05       Impact factor: 56.272

9.  Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.

Authors:  W Timothy Garvey; Donna H Ryan; Michelle Look; Kishore M Gadde; David B Allison; Craig A Peterson; Michael Schwiers; Wesley W Day; Charles H Bowden
Journal:  Am J Clin Nutr       Date:  2011-12-07       Impact factor: 7.045

10.  Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP).

Authors:  David B Allison; Kishore M Gadde; William Timothy Garvey; Craig A Peterson; Michael L Schwiers; Thomas Najarian; Peter Y Tam; Barbara Troupin; Wesley W Day
Journal:  Obesity (Silver Spring)       Date:  2011-11-03       Impact factor: 5.002

View more
  20 in total

Review 1.  Exercise resistance across the prediabetes phenotypes: Impact on insulin sensitivity and substrate metabolism.

Authors:  Steven K Malin; Zhenqi Liu; Eugene J Barrett; Arthur Weltman
Journal:  Rev Endocr Metab Disord       Date:  2016-03       Impact factor: 6.514

Review 2.  Liraglutide: a review of its use in the management of obesity.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

3.  Causal mediation analysis between resistance exercise and reduced risk of cardiovascular disease based on the Aerobics Center Longitudinal Study.

Authors:  Jiasheng Huang; Yehua Li; Angelique G Brellenthin; Duck-Chul Lee; Xuemei Sui; Steven N Blair
Journal:  J Appl Stat       Date:  2021-08-06       Impact factor: 1.416

4.  A Phase I, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Tolerance of Oil Palm Phenolics (OPP) in Healthy Volunteers.

Authors:  Nur Balqis Muhammad Ismail Tadj; Nurul 'Izzah Ibrahim; Qodriyah Haji Mohd Saad; Tg Mohd Ikhwan Tg Abu Bakar Sidik; Soon-Sen Leow; Syed Fairus; Isa Naina Mohamed
Journal:  Front Pharmacol       Date:  2022-06-20       Impact factor: 5.988

5.  The Effect of Gestational Weight Gain Across Reproductive History on Maternal Body Mass Index in Midlife: The Study of Women's Health Across the Nation.

Authors:  Franya Hutchins; Barbara Abrams; Maria Brooks; Alicia Colvin; Tiffany Moore Simas; Milagros Rosal; Barbara Sternfeld; Sybil Crawford
Journal:  J Womens Health (Larchmt)       Date:  2019-11-27       Impact factor: 2.681

6.  Obesity Pharmacotherapy is Effective in the Veterans Affairs Patient Population: A Local and Virtual Cohort Study.

Authors:  Jay Pendse; Franco Vallejo-García; Andrew Parziale; Mae Callanan; Craig Tenner; José O Alemán
Journal:  Obesity (Silver Spring)       Date:  2021-02       Impact factor: 5.002

7.  Short-term effects of a combined nutraceutical of insulin-sensitivity, lipid level and indexes of liver steatosis: a double-blind, randomized, cross-over clinical trial.

Authors:  Arrigo F G Cicero; Martina Rosticci; Angelo Parini; Martino Morbini; Riccardo Urso; Elisa Grandi; Claudio Borghi
Journal:  Nutr J       Date:  2015-03-28       Impact factor: 3.271

8.  Cross-sectional association between soda consumption and body mass index in a community-based sample of twins.

Authors:  Anna E Eney; Siny Tsang; Joseph A Delaney; Eric Turkheimer; Glen E Duncan
Journal:  Nutr J       Date:  2017-08-22       Impact factor: 3.271

9.  Persistent weight loss with a non-invasive novel medical device to change eating behaviour in obese individuals with high-risk cardiovascular risk profile.

Authors:  Peter von Seck; F Martin Sander; Leon Lanzendorf; Sabine von Seck; André Schmidt-Lucke; Mirja Zielonka; Caroline Schmidt-Lucke
Journal:  PLoS One       Date:  2017-04-12       Impact factor: 3.240

10.  Lipid profile of hyperlipidemic males after supplementation of multigrain bread containing sunflower (Helianthus annuus) seed flour.

Authors:  Gurkirat Kaur; Navjot Kaur; Amarjeet Kaur
Journal:  J Food Sci Technol       Date:  2020-09-26       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.